NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Valneva SE (VALN) Stock Analysis

Valneva SE (VALN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

VALN

$5.56

−$0.13 (−2.28%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VALN with… →

VALN Key Statistics

As of Oct 21, 2026
Trading
Open
$5.75
Previous Close
$5.69
Day's Range
5.53–5.75
52-Week Range
4.75–12.18
Volume
137.26K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.26
Valuation
Market Cap
$527.22M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
4.67
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.69
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.10
Financials (FY)
Revenue (FY)
$174.66M+3.00%
Net Income (FY)
−$115.19M
Profit marginThe share of revenue left as profit after all costs and taxes.
−110.29%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
94.82M
1-Year Return
−43.67%
Dividend and dates
Avg Volume
74.69K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, VALN closed at $5.56, −43.67% over 1 year.

Valneva SE (VALN) has a market capitalization of $527.22M.

In fiscal 2025, VALN reported revenue of $174.66M.

VALN Stock Return by Calendar Year

Valneva SE (VALN) return since May 2021: what $10,000 became

1 year
$10,000 $5,633
−43.67%
5 years
$10,000 $1,240
−87.60%
Since May 2021
$10,000 $2,105
−78.95%

If you had invested $10,000 in Valneva SE (VALN) at the close on May 5, 2021, the earliest close on record here, it would have been worth $2,105 at the close on October 21, 2026: −78.95% in total, −24.82% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−36.96%
2025+101.74%
2024−57.84%
2023−18.48%
2022−77.09%
2021 (partial year)+110.19%

As of October 21, 2026.

VALN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$174.66M−$115.19M−66.0%
2024$169.58M−$12.25M−7.2%
2023$153.71M−$101.43M−66.0%
2022$361.30M−$143.28M−39.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$174.66M$67.52M−$81.63M−$115.19M−66.0%
2024$169.58M$71.04M−$77.77M−$12.25M−7.2%
2023$153.71M$52.84M−$82.11M−$101.43M−66.0%
2022$361.30M$36.86M−$113.44M−$143.28M−39.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VALN Valuation vs Biotechnology Median

Median of 608 stocks
MetricVALNBiotechnology medianvs median
P/S ratio3.6913.300.3x the median
Profit margin−110.29%−38.31%72.0 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Valneva SE (VALN) carries a market capitalisation of $527.22M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 620.

The most recent close on file for VALN is $5.56, dated October 21, 2026. That is −$0.13 (−2.28%) against the previous close. Over the past 52 weeks the price has ranged from $4.75 to $12.18. The latest close sits 17.05% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $174.66M. That is +3.00% against the prior fiscal year, when revenue was $169.58M. The same year closed with a net loss of $115.19M. Profit margin runs at −110.29%. That is 72 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −2.1.

Across the 4 fiscal years on file, revenue moves from $361.30M in 2022 to $174.66M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 4.67. Measured against sales, the shares trade at 3.69 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is −43.67%. Across 5 years the annualized return works out at −34.13%. The reported beta is 1.26. Annualized volatility over the trailing 5 years is 88.17%.

Growth & Income

No dividend is on file for VALN.

The strongest complete calendar year on file is 2025 at +101.74%; the weakest is 2022 at −77.09%. Of the 4 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is −36.96% year to date.

Peer Comparison

Valneva SE (VALN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Valneva SE VALN $527.22M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Valneva SE has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.

Visit website →